Once-Daily Indacaterol Acetate, Glycopyrronium Bromide, and Mometasone Furoate as a Fixed-Dose Combination in Japanese Patients with Inadequately Controlled Asthma: A Multicenter, 52-Week Safety Study

被引：0
|
作者：
Sagara, H. [1 ]
D'Andrea, P. [2 ]
Tanase, A. [3 ]
Pethe, A. [2 ]
Tanaka, Y. [4 ]
Matsuo, K. [4 ]
Hosoe, M. [3 ]
机构：
[1] Showa Univ, Sch Med, Dept Med, Div Allergol & Resp Med, Tokyo, Japan
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novarts Pharma KK, Tokyo, Japan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3012
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy of once-daily medium- or high-dose mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus twice- daily high-dose fluticasone/salmeterol (FLU/SAL) to control nocturnal symptoms in patients (pts) with inadequately controlled asthma
    Chapman, K. R.
    Smit, R. Van-Zyl
    Mezzi, K.
    Brittain, D.
    Kerstjens, H. A.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [32] Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study
    van Zyl-Smit, Richard N.
    Kruell, Matthias
    Gessner, Christian
    Gun, Yasuhiro
    Noga, Oliver
    Richard, Alexia
    de los Reyes, Amy
    Shu, Xu
    Pethe, Abhijit
    Tanase, Ana-Maria
    D'Andrea, Peter
    LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : 987 - 999
  • [33] Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials
    Tashkin, Donald P.
    Doherty, Dennis E.
    Kerwin, Edward
    Matiz-Bueno, Carlos E.
    Knorr, Barbara
    Shekar, Tulin
    Gates, Davis
    Staudinger, Heribert
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 7 : 73 - 86
  • [34] Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study
    Bulent Enis Sekerel
    Haylene Nell
    Istvan Laki
    Tatiana Pak
    Edgar Contreras
    Adam Kolarz
    Peter D’Andrea
    Volkan Manga
    Monish Jain
    Soniya Vaidya
    Michele Valentin
    Biswajit Sen
    Clinical Drug Investigation, 2023, 43 : 719 - 728
  • [35] Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study
    Sekerel, Bulent Enis
    Nell, Haylene
    Laki, Istvan
    Pak, Tatiana
    Contreras, Edgar
    Kolarz, Adam
    D'Andrea, Peter
    Manga, Volkan
    Jain, Monish
    Vaidya, Soniya
    Valentin, Michele
    Sen, Biswajit
    CLINICAL DRUG INVESTIGATION, 2023, 43 (09) : 719 - 728
  • [36] One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies
    Chapman, Kenneth
    van Zyl-Smit, Richard
    Maspero, Jorge
    Kerstjens, Huib A. M.
    Gon, Yasuhiro
    Hosoe, Motoi
    Tanase, Ana-Maria
    Pethe, Abhijit
    Shu, Xu
    D'Andrea, Peter
    BMJ OPEN RESPIRATORY RESEARCH, 2021, 8 (01)
  • [37] Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial
    Rhee, Chin Kook
    Park, Hye Yun
    Park, Jeong-Woong
    Lee, Ji-Hyun
    Kim, Tae-Hyung
    Lee, Sei Won
    Jung, Ji Ye
    Kim, Song
    Hwang, Yong Il
    Jung, Ki-Suck
    TRIALS, 2017, 18
  • [38] Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial
    Chin Kook Rhee
    Hye Yun Park
    Jeong-Woong Park
    Ji-Hyun Lee
    Tae-Hyung Kim
    Sei Won Lee
    Ji Ye Jung
    Song Kim
    Yong Il Hwang
    Ki-Suck Jung
    Trials, 18
  • [39] Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial (vol 7, pg 43, 2012)
    Tashkin, D. P.
    Doherty, D. E.
    Kerwin, E.
    Matiz-Bueno, C. E.
    Knorr, B.
    Shekar, T.
    Banerjee, S.
    Staudinger, H.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 7 : 765 - 765
  • [40] Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial
    Kawamori, Ryuzo
    Haneda, Masakazu
    Suzaki, Keiko
    Cheng, Gang
    Shiki, Kosuke
    Miyamoto, Yuki
    Solimando, Fernando
    Lee, Christopher
    Lee, Jisoo
    George, Jyothis
    DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2200 - 2209
12345